Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0901 in CLDN18.2-positive advanced solid tumors
jRCT2031230569Phase 1Recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of sonesitatug vedotin in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, pancreatic adenocarcinoma (PDAC) and 3 more (4 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability of AZD0901 and Objective response rate (ORR). Started Jan 2024; status: recruiting.
02
Drugs
sonesitatug vedotin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomapancreatic adenocarcinoma (PDAC)biliary adenocarcinomacholangiocarcinoma (CCA)
Beyond the preview
Go deeper on jRCT2031230569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230569.